Amgen and Veeva Partner to Accelerate Clinical Trials with Veeva Clinical Platform

Veeva Systems has partnered with Amgen to enhance clinical trial operations using the Veeva Clinical Platform, aiming to accelerate drug development. The collaboration aims to leverage advanced technology to unlock new capabilities for Amgen, speeding up drug development.

Veeva Systems (NYSE: VEEV) has announced a strategic collaboration with Amgen to enhance clinical trial operations using the Veeva Clinical Platform. The partnership aims to leverage advanced technology to unlock new capabilities for Amgen, thereby speeding up drug development and bringing innovative treatments to patients more quickly.

Amgen, a global leader in biotechnology, will employ the Veeva Clinical Platform to support and identify efficiencies across the clinical trial process. The platform, which includes tools such as CTMS, EDC, and eTMF, is designed to streamline clinical trials from study startup to close and automate a connected data flow.

Scott Skellenger, senior vice president and chief information officer at Amgen, commented, "In collaboration with Veeva, we're leveraging advanced technology to unlock new capabilities for our end-to-end trial operations, which are expected to further strengthen our ability to bring innovative treatments to patients with speed and scale" [1].

Jim Reilly, president of Veeva Development Cloud, added, "We're excited to help Amgen further advance clinical development. Veeva Clinical Platform will provide the backbone for standard and connected processes that can speed the delivery of life-saving drugs to patients in need" [1].

As part of the collaboration, Veeva Business Consulting will support Amgen through implementation and change management. This strategic partnership is part of Veeva's broader commitment to innovation and product excellence, serving more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs [2].

The Veeva Clinical Platform is a comprehensive solution that includes a range of clinical operations and data applications. It aims to provide a more efficient and connected clinical trial process, potentially reducing costs and accelerating the time it takes to bring new medicines to market.

The collaboration between Veeva and Amgen is a significant step forward in the life sciences industry, demonstrating how advanced technology and strategic partnerships can drive innovation and improve patient outcomes. As the industry continues to face rising R&D costs and regulatory pressures, such partnerships are becoming increasingly important.

References:
[1] https://www.prnewswire.com/news-releases/veeva-announces-collaboration-with-global-biotech-to-further-accelerate-clinical-trial-innovation-302540574.html
[2] https://seekingalpha.com/news/4490072-veeva-partners-with-amgen-to-speed-up-clinical-trials